Patients with aberrations in two genes respond better to drugs blocking a well-known cancer pathway
Cancer patients with mutations or variations in two genes -– PIK3CA and PTEN -– who have failed to respond to several, standard treatments, respond significantly better to anti-cancer drugs that inhibit these genes' pathways ...
Nov 7, 2012
0
0